{"id":564929,"date":"2025-01-02T00:00:00","date_gmt":"2025-01-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0051-biopharma-obesity-epidemiology-epidemiology-dashboard\/"},"modified":"2026-04-27T11:14:52","modified_gmt":"2026-04-27T11:14:52","slug":"epidmd0051-biopharma-obesity-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0051-biopharma-obesity-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Obesity &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of obesity \/ overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total obesity \/ overweight prevalent cases for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s obesity \/ overweight forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of obesity \/ overweight and the number of new diagnoses of obesity \/ overweight?<\/li>\n<li>Of all people diagnosed with obesity \/ overweight, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity \/ overweight over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total obesity\u00a0prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following obesity \/ overweight subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total\u00a0overweight\u00a0prevalent cases<\/li>\n<li>Total obesity prevalent cases after effective usage of GLP-1RAs<\/li>\n<li>Drug and non-drug-eligible overweight prevalent cases<\/li>\n<li>Severity\u00a0<\/li>\n<li>Diagnosed and undiagnosed prevalent cases<\/li>\n<li>Diagnosed drug and non-drug-treated obesity prevalent cases<\/li>\n<li>Diagnosed drug and non-drug-eligible overweight prevalent cases<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-564929","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564929\/revisions"}],"predecessor-version":[{"id":565393,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564929\/revisions\/565393"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=564929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}